According to the report
analysis, ‘Global
Companion Diagnostics Market - Drivers, Restraints, Opportunities,
Trends, and Forecasts: 2018-2024’ states that there are numerous key players
which recently performing in the companion diagnostics market more positively
for leading the fastest market growth and accounting the highest value of
market share across the globe in the coming years while developing the
applications of the companion diagnostics and increasing requirement for the
next-generation sequencing includes F. Hoffmann-La Roche Ltd, Qiagen N.V.,
Abbott Laboratories, Myriad Genetics, Agilent Technologies, Inc., BioMerieux
S.A., Danaher Corporation (Leica Microsystems AG), Resonance Health Limted,
Thermo Fisher Scientific, Inc., Genomic Health, Inc and several others.
The companion diagnostics
are the molecular tests that deliver the indispensable information for the
security and efficient usage of the corresponding drug. These tests support the
healthcare professionals to choose whether a detailed treatment product assistances
patient for curing disease, expect drug toxicities, off-target effects of
treatment, and several other contrary effects correlated to the drug. It is
also effective utilized during the clinical trials to direct the treatment,
which can develop therapy comebacks and treatment results. In the present era,
there are over 20 appropriate or unfurnished companion diagnostic tests and
major of the tests are for cancer treatments targeting mutation.
Furthermore, according to
the study of World Health Organization, nearly 14 million new cancer cases were
established and is anticipated to increase by around 70% over the next 2
decades. The inclination of snowballing incidence of cancer & infectious
diseases is contagious up even in underdeveloped regions owing to the increased
acceptance of the Western lifestyle, which is predicted to propel the growth of
the companion diagnostics market in near years.
Nonetheless, the companion
diagnostics market is flourishing more actively owing to the augmenting patient
base for infectious diseases & cancer across the globe, extraordinary acceptance
of the companion diagnostics, augmenting requirement for the companion
diagnostics, and unindustrialized applications of companion diagnostics. For
instance, the low mindfulness &shortage of the professionals to conduct
tests and uncomplimentary reimbursement development in advanced &underdeveloped
economies are few of the factors hindering the market growth to an extent.
However, in February 2017,
the Roche proclaimed the launch of Elecsys AMH Plus immunoassay, the first
companion diagnostic to be permitted for the effective usage in fertility. The
key market players are acceptance product endorsements that are facilitating
them to augment the market share. For instance, in June 2017, the US FDA
approved the approval to Thermo Fisher Scientific for NGS-based test recognized
as the OncomineDx Target test, which immediately appraises 23 genes clinically
associated to NSCLC.
The Global Companion
Diagnostics market is predicted to observe an efficient CAGR of 19.6% during
the forecast period of 2018-2024. Whereas, the market of companion diagnostics
is sectored across the globe which majorly involves North America, Europe, Asia
Pacific, and Rest of the World (RoW). North America is set to be the foremost region
for the companion diagnostics market growth followed by Europe, Asia Pacific,
and Rest of the World. Therefore, in the near future, it is anticipated that
the market of companion diagnostics will increase across the globe more significantly
over the coming years.
For more information on the research
report, refer to below link:
Related reports
Contact Us:-
Ken
Research
Ankur
Gupta, Head Marketing & Communications
+91-9015378249
No comments:
Post a Comment